Twist Bioscience Reports Fiscal Third Quarter 2026 Financial Results

Twist Bioscience Corporation announced its financial results for the third quarter ended June 30, 2026. The company achieved a record revenue of $118.4 million, representing a 23% increase compared to the same period in fiscal year 2025, marking the 14th consecutive quarter of sequential growth. Gross margin improved to 52.8%, a 120 basis point increase quarter-over-quarter. DNA Synthesis and Protein Solutions revenue grew by 39% to $56.6 million, while NGS Applications revenue increased by 12% to $61.8 million. The company raised its fiscal year 2026 revenue guidance to $456-$457 million, an increase of $12 million at the midpoint, and reiterated its expectation to achieve adjusted EBITDA breakeven in the fourth quarter of fiscal year 2026. Despite an increased net loss of $35.1 million for the quarter, the company highlighted a strong cash position of approximately $167 million in cash, cash equivalents, and short-term investments as of June 30, 2026. Recent operational highlights include significant growth in shipped genes and the successful commercial launch of Twist Complex Genes.